Cargando…
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a be...
Autores principales: | Loso, Jefferson, Lund, Natalie, Avanesov, Maxim, Muschol, Nicole, Lezius, Susanne, Cordts, Kathrin, Schwedhelm, Edzard, Patten, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104487/ https://www.ncbi.nlm.nih.gov/pubmed/30159316 http://dx.doi.org/10.3389/fcvm.2018.00108 |
Ejemplares similares
-
Association of Asymmetric Dimethylarginine and Diastolic Dysfunction in Patients with Hypertrophic Cardiomyopathy
por: Cordts, Kathrin, et al.
Publicado: (2019) -
Comparison of classical Fabry and its p.D313Y and p.A143T variants by cardiac T1 mapping, LGE and feature tracking myocardial strain
por: Avanesov, Maxim, et al.
Publicado: (2023) -
Extent of late gadolinium enhancement in patients with hypertrophic cardiomyopathy in correlation with serum MMP9 as an indicator of myocardial fibrosis
por: Avanesov, Maxim, et al.
Publicado: (2014) -
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018) -
Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies
por: Averbuch, Tauben, et al.
Publicado: (2023)